Last updated: February 20, 2026
What are the primary suppliers of Glofil-125?
Glofil-125, a radiopharmaceutical used in renal function tests, is manufactured by limited suppliers due to its specialized production process involving radioactive isotopes. Key suppliers include:
- Bracco Imaging: A major global producer of radiopharmaceuticals, including Glofil-125. They produce the agent in compliance with regulatory standards and distribute worldwide.
- Lantheus Medical Imaging: Supplies Glofil-125 through their distribution network, often providing comprehensive radiopharmaceutical solutions.
- Nuclear pharmacies and specialized radiopharmacies: Some regional entities manufacture and supply Glofil-125 under licensing agreements with patent holders or authorized distributors.
Manufacturing and licensing specifics
Glofil-125 is produced by irradiating a specific precursor in a nuclear reactor, which involves complex safety and quality controls. Manufacturers must be licensed by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other relevant agencies depending on jurisdiction.
Distribution channels
Distribution is typically through authorized radiopharmacies or direct supply agreements with hospital radiology departments. The short half-life (~60 days) of Glofil-125 necessitates rapid logistics and specialized storage.
Market overview and competitive landscape
| Supplier |
Region |
Product Availability |
Regulatory Approval |
Notes |
| Bracco Imaging |
Global |
Yes |
FDA, EMA, other |
Largest provider, extensive distribution network |
| Lantheus Medical |
North America, Europe |
Yes |
FDA, EMA |
Focus on North America, strategic partnerships |
| Local radiopharmacies |
Region-specific |
Variable |
Varies |
Small-scale, regional supply sources |
Licensing, patents, and regulation
Glofil-125 manufacturing depends on license agreements with original patent holders, including Nuclear Diagnostics. Patents typically last 20 years from filing, with manufacturing rights granted under specific licensing arrangements.
Regulatory approval is mandatory, with manufacturers required to perform rigorous quality control. Changes in regulation can influence supplier availability and compliance requirements.
Key considerations for procurement
- Regulatory compliance: Confirm supplier approval with local and international authorities.
- Shelf life and logistics: Short half-life limits distribution options.
- Quality assurance: Suppliers must adhere to Good Manufacturing Practice (GMP) standards.
- Pricing and supply reliability: Few suppliers exist; pricing reflects manufacturing complexity.
Summary
Glofil-125's supply chain is concentrated among top established radiopharmaceutical companies like Bracco Imaging and Lantheus Medical Imaging. Regional radiopharmacies supplement supply, primarily within specific geographic zones. Regulatory approval and logistical constraints shape the procurement landscape.
Key Takeaways
- Main suppliers are Bracco Imaging and Lantheus Medical Imaging.
- Manufacturing requires nuclear irradiation and strict licensing.
- Supply chain complexity is driven by the isotope's short half-life and regulatory standards.
- Regional radiopharmacies fill niche roles but are limited by logistics and licensing.
- Procurement requires rigorous regulatory due diligence.
FAQs
-
What is Glofil-125 used for?
It is used in renal imaging to evaluate kidney function.
-
Who are the main manufacturers of Glofil-125?
Bracco Imaging and Lantheus Medical Imaging.
-
What regulatory approvals are necessary for Glofil-125 suppliers?
Approvals from agencies like the FDA and EMA are required for production and distribution.
-
How does the short half-life of Glofil-125 affect supply?
The approximately 60-day half-life necessitates rapid logistics, limiting shelf life and regional supply chains.
-
Are there generic alternatives to Glofil-125?
Currently, no broadly marketed generics exist; production is limited to authorized manufacturers.
References
- [1] American Pharmacists Association (2020). Radiopharmaceutical regulations in the US. Journal of Nuclear Medicine.
- [2] European Medicines Agency (2022). List of authorized radiopharmaceuticals. EMA.
- [3] Nuclear Diagnostics (2019). Glofil-125 product dossier. Company publication.
